This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Published . Updated .
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Directly affected
- GRAL Grail
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
A fund of health-care companies
- XBI SPDR S&P Biotech
A fund of biotechnology companies
- UNH UnitedHealth
A large health insurer
- JNJ Johnson & Johnson
A large health-care company
- LLY Eli Lilly
A large drug maker
- PFE Pfizer
A large drug maker
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The price since 23 Sep 2026: Acadia Healthcare (ACHC) versus the S&P 500
Since the first closing price after “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” Acadia Healthcare (ACHC) is +8.55%. The S&P 500 fund (SPY) is -0.09% over the same days, a +8.64% difference versus the market.
Filings that name Acadia Healthcare (ACHC) around 23 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 6 days after publication, inside 30 days. The filing is listed beside the story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 12 days before publication, inside 30 days. The filing is listed beside the story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 51 days before publication, inside 60 days. The filing is listed beside the story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 55 days before publication, inside 60 days. The filing is listed beside the story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies carried with this story
- ACHC Acadia Healthcare
In “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence in the 23 Sep 2026 story “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval.” Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval,” the 23 Sep 2026 this story story.
Acadia Healthcare (ACHC) is on the page because GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the Acadia Healthcare (ACHC) price range
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
100 out of 100
“This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval” scores 100 out of 100. The score uses 6 linked companies.